FDA Submission Overview for Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate
The FDA has received a new drug application (NDA219804) for a combination therapy including Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate.
Asset / Drug
Drug and asset intelligence for Dolutegravir with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A study is underway to evaluate the efficacy and safety of a two-drug regimen versus a three-drug regimen in treatment-naive HIV-1 patients.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.